Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 10/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4233098 | 0.99 | F2R (0.98) | F2RRAB9ANPC1CXCR3KMT2A | |
| Bromide SCHEMBL2346025 | 0.99 | F2R (0.98) | F2RRAB9ANPC1CXCR3KMT2A | |
| SCHEMBL2347450 | 0.88 | F2R (0.79) | F2RRAB9ANPC1CXCR3KMT2A | |
| Hydrochloric Acid SCHEMBL21797201 | 0.87 | F2R (0.78) | F2RRAB9ANPC1CXCR3KMT2A | |
| Bromide SCHEMBL2349567 | 0.87 | F2R (0.78) | F2RRAB9ANPC1CXCR3KMT2A | |
| Bromide SCHEMBL6748476 | 0.86 | F2R (0.77) | F2RRAB9ANPC1CXCR3KMT2A | |
| Bromide SCHEMBL6746409 | 0.85 | F2R (0.82) | F2RRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL12393183 | 0.85 | F2R (1.00) | F2RKMT2AMEN1SMN1; SMN2MAPT | |
| Bromide SCHEMBL6746431 | 0.84 | F2R (0.74) | F2RRAB9ANPC1CXCR3KMT2A | |
| Bromide SCHEMBL6746448 | 0.84 | F2R (0.71) | F2RRAB9ANPC1CXCR3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163078-A1 | Mycobacterial Disease Detection, Treatment, and Drug Discovery | THE UAB RESEARCH FOUNDATION (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163078-A1 | Mycobacterial Disease Detection, Treatment, and Drug Discovery | THE UAB RESEARCH FOUNDATION (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2535426-A2 | Mycobacterial disease detection, treatment, and drug discovery | THE UAB RESEARCH FOUNDATION (US) | 2012-12-19 | — | — | EP | disclosed |
| US-8008354-B2 | TNF-family death receptor ligand-resistant cells to one or more TNF-family death receptor ligands; screening for molecules that restore sensitivity of tumor cells to TNF-family death receptors and so are useful therapeutic adjuncts to agents such as recombinant TRAIL and tumor vaccines; kills tumor cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008354-B2 | TNF-family death receptor ligand-resistant cells to one or more TNF-family death receptor ligands; screening for molecules that restore sensitivity of tumor cells to TNF-family death receptors and so are useful therapeutic adjuncts to agents such as recombinant TRAIL and tumor vaccines; kills tumor cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008354-B2 | TNF-family death receptor ligand-resistant cells to one or more TNF-family death receptor ligands; screening for molecules that restore sensitivity of tumor cells to TNF-family death receptors and so are useful therapeutic adjuncts to agents such as recombinant TRAIL and tumor vaccines; kills tumor cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-08-30 | — | — | US | disclosed |
| US-20090068197-A1 | MYCOBACTERIAL DISEASE DETECTION, TREATMENT, AND DRUG DISCOVERY | THE UAB RESEARCH FOUNDATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090068197-A1 | MYCOBACTERIAL DISEASE DETECTION, TREATMENT, AND DRUG DISCOVERY | THE UAB RESEARCH FOUNDATION (US) | 2009-03-12 | — | — | US | disclosed |
| EP-1996732-A2 | MYCOBACTERIAL DISEASE DETECTION, TREATMENT, AND DRUG DISCOVERY | THE UAB RESEARCH FOUNDATION (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20080206287-A1 | Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands | REED JOHN C | 2008-08-28 | — | — | US | disclosed |
| US-20080206287-A1 | Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands | REED JOHN C | 2008-08-28 | — | — | US | disclosed |
| US-20080206287-A1 | Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands | REED JOHN C | 2008-08-28 | — | — | US | disclosed |
| US-20080166378-A1 | DEATH RECEPTOR SENSITIZING COMPOUNDS AND METHODS OF USE THEREFOR | THE BURNHAM INSTITUTE | 2008-07-10 | — | — | US | disclosed |
| US-20080166378-A1 | DEATH RECEPTOR SENSITIZING COMPOUNDS AND METHODS OF USE THEREFOR | THE BURNHAM INSTITUTE | 2008-07-10 | — | — | US | disclosed |
| US-20080166378-A1 | DEATH RECEPTOR SENSITIZING COMPOUNDS AND METHODS OF USE THEREFOR | THE BURNHAM INSTITUTE | 2008-07-10 | — | — | US | disclosed |
| WO-2008036244-A1 | USE OF CYCLOSPORIN A TO SENSITIZE RESISTANT CANCER CELLS TO DEATH RECEPTOR LIGANDS | THE BURHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007101274-A3 | MYCOBACTERIAL DISEASE DETECTION, TREATMENT, AND DRUG DISCOVERY | UAB RESEARCH FOUNDATION (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007101274-A2 | MYCOBACTERIAL DISEASE DETECTION, TREATMENT, AND DRUG DISCOVERY | THE UAB RESEARCH FOUNDATION (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007101274-A2 | MYCOBACTERIAL DISEASE DETECTION, TREATMENT, AND DRUG DISCOVERY | THE UAB RESEARCH FOUNDATION (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163078-A1 | Mycobacterial Disease Detection, Treatment, and Drug Discovery | ANP32B, ANP32A, MRPL21 | F2R 4019/4885RAB9A 1409/4885NPC1 2974/4885 |
| US-20090068197-A1 | MYCOBACTERIAL DISEASE DETECTION, TREATMENT, AND DRUG DISCOVERY | ANP32B, ANP32A, MRPL21 | F2R 4019/4885RAB9A 1409/4885NPC1 2974/4885 |
| US-20080206287-A1 | Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands | TNFRSF1A, TNFRSF9, CD40 | F2R 2764/4885RAB9A 4474/4885NPC1 3024/4885 |
| US-20080166378-A1 | DEATH RECEPTOR SENSITIZING COMPOUNDS AND METHODS OF USE THEREFOR | BAD, BAK1, MCL1 | F2R 356/4885RAB9A 4650/4885NPC1 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.